IPCALAB2018-04-012018-06-30in-bse-fin:OneOperatingExpenses01Member IPCALAB2018-04-012018-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2018-04-012018-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2018-04-012018-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2018-04-01 2019-03-31 2018-07-26 INR Crores First quarter Single segment Pharmaceuticals 2018-04-01 2018-06-30 Unaudited Standalone 8539300000.00 136300000.00 8675600000.00 2532700000.00 356800000.00 -112300000.00 1954000000.00 49300000.00 444900000.00 2668000000.00 7893400000.00 782200000.00 0.00 782200000.00 162900000.00 -35900000.00 127000000.00 0.00 655200000.00 0.00 0.00 0.00 0.00 655200000.00 26100000.00 681300000.00 0.00 0.00 252700000.00 2 5.19 5.19 0.00 0.00 5.19 5.19 Notes : n1 The above unaudited financial results as reviewed by the Audit Committee, were approved and taken on    record by the Board of Directors in their meeting held on August 9 2018. n n2  The Auditors of the Company have carried out the limited review of the above unaudited financial results. n n3. Effective April 1 2018 the Company has adopted Ind AS 115 on Revenue from Contracts with Customers      using the cumulative catch-up transition method. The adoption of this standard did not have any material      impact on the above financial results. n n4. Revenue from Operations for the quarter ended June 30 2018 and March 31 2018 are shown net of Goods     and Service Tax (GST). Net Sales for the corresponding quarter is shown inclusive of excise duty and for the    financial year ended March 31, 2018 includes excise duty upto June 30, 2017. For comparision purposes     revenue excluding excise duty is given below: n n (Rs.Crores) n nSr. nNo.tParticularst Quarter Endedt                                                                    Year Ended ntt                  June 30,2018   March 31, 2018 June 30, 2017                March 31, 2018 n                                                    (Unaudited)      (Audited)          (Unaudited)                         (Audited) n t nA.tTotal Income from           853.93 781.56t           713.42t                       3219.21 n                operationst nB.tExcise Duty on sales n                (included in other expenses)ttt            10.28t                            10.28 nC.tTotal Income from operations n                 excluding Excise duty on Sales nt    (A-B)                              853.93 781.56t           703.14                                 3208.93 n n5 The Board of Directors have alloted 153000 fully paid - up equity shares of Rs.2/- each at Rs. 300/- per share     on May 29 2018 upon exercise of options granted under Ipca Laboratories Ltd. Employees Stock Option     Scheme - 2014. n n6 The figures of quarter ended March 31 2018 are the balancing figures between audited figures in respect      of the full financial year ended March 31 2018 and figures upto the third quarter ended December 31 2017       which were subjected to Limited Review by the Statutory Auditors. n n7. The Company has only one reportable primary business segment viz. Pharmaceuticals. n n8. Figures for the previous period have been regrouped / re-classified to conform to the figures of the       current period. nt                                             n Other Expenses 2668000000.00